Yi Zhang1, Shibu Lin2, Xianjin Yang1, Rong Wang1, Lingyan Luo3. 1. Department of General Surgery, The First People's Hospital of Neijiang, Neijiang, Sichuan, China. 2. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China. 3. Department of Scientific Research and Education, The First People's Hospital of Neijiang, Neijiang, Sichuan, China.
Abstract
BACKGROUND: Numerous studies have reported the relationship between systemic immune-inflammation index (SII) and prognosis in gastrointestinal (GI) cancers, but no consensus has been reached. We aimed to systematically evaluate the prognostic value of SII in patients with GI cancers. METHODS: Relevant published papers regarding the prognostic value of SII in patients with GI cancers were obtained from a number of electronic databases. The overall hazard ratios and the corresponding 95% confidence intervals (95% CIs) were calculated using a fixed or random effects model to assess the relationship between SII and prognosis through Stata SE 12.0. RESULTS: A total of 24 eligible published articles with 9,626 patients were included. From the pooled results, we found that high SII indicated worse overall survival (OS) in patients with GI cancers (HR = 1.52, 95%CI: 1.29-1.74). And patients with high SII had poorer disease-free survival (HR: 2.28, 95% CI: 1.46-3.10), time to recurrence (HR: 1.70, 95% CI: 1.11-2.30), and recurrence-free survival (HR: 1.60, 95% CI: 1.19-2.00) when compared with those with low SII values. CONCLUSIONS: SII might serve as a noninvasive and powerful tool for predicting survival outcome in patients with GI cancers.
BACKGROUND: Numerous studies have reported the relationship between systemic immune-inflammation index (SII) and prognosis in gastrointestinal (GI) cancers, but no consensus has been reached. We aimed to systematically evaluate the prognostic value of SII in patients with GI cancers. METHODS: Relevant published papers regarding the prognostic value of SII in patients with GI cancers were obtained from a number of electronic databases. The overall hazard ratios and the corresponding 95% confidence intervals (95% CIs) were calculated using a fixed or random effects model to assess the relationship between SII and prognosis through Stata SE 12.0. RESULTS: A total of 24 eligible published articles with 9,626 patients were included. From the pooled results, we found that high SII indicated worse overall survival (OS) in patients with GI cancers (HR = 1.52, 95%CI: 1.29-1.74). And patients with high SII had poorer disease-free survival (HR: 2.28, 95% CI: 1.46-3.10), time to recurrence (HR: 1.70, 95% CI: 1.11-2.30), and recurrence-free survival (HR: 1.60, 95% CI: 1.19-2.00) when compared with those with low SII values. CONCLUSIONS: SII might serve as a noninvasive and powerful tool for predicting survival outcome in patients with GI cancers.
Authors: Maria Hernandez-Ainsa; Raul Velamazan; Angel Lanas; Patricia Carrera-Lasfuentes; Elena Piazuelo Journal: Front Med (Lausanne) Date: 2022-06-20
Authors: Hicaz Zencirkiran Agus; Serkan Kahraman; Cagdas Arslan; Ceren Yildirim; Mehmet Erturk; Ali Kemal Kalkan; Mustafa Yildiz Journal: J Saudi Heart Assoc Date: 2020-04-17
Authors: Pranav Murthy; Mazen S Zenati; Amr I Al Abbas; Caroline J Rieser; Nathan Bahary; Michael T Lotze; Herbert J Zeh; Amer H Zureikat; Brian A Boone Journal: Ann Surg Oncol Date: 2019-12-02 Impact factor: 5.344